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Abstract
Several novel tri-peptide cationic lipids were designed and synthesized for delivering DNA and 
siRNA. They have tri-lysine and tri-ornithine as head groups, carbamate group as linker and 12 
and 14 carbon atom alkyl groups as tails. These tri-peptide cationic lipids were prepared into 
cationic liposomes for the study of the physicochemical properties and gene delivery. Their 
particle size, Zeta potential and DNA-binding were characterized to show that they were suitable 
for gene transfection. The further results indicate that these lipids can transfer DNA and siRNA 
very efficiently into NCI-H460 and Hep-2 tumor cells. The selected lipid, CDO14, was able to 
deliver combined siRNAs against c-Myc and VEGF for silencing distinct oncogenic pathways in 
lung tumors of mice, with little in vitro and in vivo toxicity.
1 Introduction
Viral vectors and non-viral vectors are widely used to modulate gene expression in target 
tissues to correct genetic defects for gene therapeutic application. Viral vectors, such as 
adenovirus vectors, adeno-associated virus vectors, or retrovirus vectors, have been applied 
in clinical trials.1–3 However, some side effects including immunoresponse and infection 
have been reported.4–5 Non-viral gene delivery systems have, on one hand, been 
demonstrated as standard tools for in vitro transfection with many commercially available 
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kits.6–8 On the other hand, they are regarded as a promising approach for the treatment of 
genetic diseases and cancers.9–12
Among these non-viral vectors, peptide cationic lipids have drawn great attention,13–18 as 
peptides are more biocompatible. Peptides and their derivatives have been used for 
restraining cancer cell migration, curing anti-thrombosis, treating acute renal failure, 
reducing anti-inflammation and promoting skin regeneration, etc. But the isolated small 
peptides are easily degraded by enzymes in vivo, and they could be cleared very 
quickly.19–20 People found that the introduction of peptide groups into lipids can prolong 
their half-life in vivo and enhance targeting thereof.21
Therefore, peptides based cationic lipids have shown more superiorities over other cat ionic 
lipids, such as good biodegradability, excellent biocompatibility and targeting ability to 
cells, and potential application in improving the delivery of gene therapeutics.22–24 
However, the current peptides based cationic lipids still hold some limitations.25–26 
Therefore, we designed and synthesized a series of novel tri-peptide cationic lipids CDL12, 




9-Fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu), o-(7-azabenzotriazol-1-yl)-
N,N,N',N'-te-tramethyluronium hexafluo-rophosphate (HATU), lauryl alcohol, myristyl 
alcohol, N,N’-carbonyldiimidazole (CDI), diethylenetriamine, 3-amino-1,2-propanediol, 
Lysine and Ornithine were purchased from Shanghai Aladdin Industrial Inc. (China). 
Lipofectamine 2000 was purchased from Invitrogen Life Technologies (USA). 1,2-
Dioleoyl-3-trimetry-lammonium-propane chloride salt (DOPE) and anti-luciferase siRNA 
were purchased from Sigma-Aldrich (USA). 1,2-Dioleoyl-3-trimethylammoniumpropane 
(DOTAP) was purchased from Roche Shanghai (China). Hep-2 and NCI-H460 cells were 
purchased from the Institute of Biochemistry and Cell Biology (China). A549 cells were 
from Leaf’s lab of the University of North Carolina at Chapel Hill. DMEM, RPMI1640, 
fetal bovine serum (FBS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) were purchased from Gibco (USA). Green fluorescent protein (pGFP-N2) and 
luciferase (pGL3) plasmid vectors were purchased from Sangon Biotech Co. Ltd. (China), 
and extracted in our lab. Bright-Glo™ Luciferase Assay System was purchased Promega 
Biotech Co. Ltd. (Beijing, China). All other chemicals were of reagent grade.
Synthesis of lipids
The synthesis of these lipids was performed as follows, using CDL12 as an example 
(Scheme 1): CDI was added to lauryl alcohol in toluene and kept at reflux for 3 h. 
Diethylenetriamine was added. After another 3 h, the solvent was evaporated. The crude 
product was recrystallised from the mixture solvent of ethanol/water to give intermediate 1. 
Boc2O in acetone was added to L-Lys aqueous solution. CuSO4·5H2O was added and kept 
stirring for 14 h at room temperature. Anhydrous sodium carbonate, 8-hydroxyquinoline and 
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Fmoc-OSu were added. The solution was stirred at room temperature for 6~7 h before being 
filtered. The filtrate was cooled to 0 °C, and pH was adjusted to 2~3 with HCl solution. The 
crude product was recrystallised from the mixture solvent of acetonitrile and petroleum ether 
to give intermediate 2 as Fmoc-Lys (Boc)-OH.
For the construction of CDL12, intermediate 2 was added to HATU in dichloromethane. 
After reaction of 1 h, dichloromethane solution of intermediate 1 was added. Boc group was 
removed with CHCl3/TFA (1:1) and Fmoc group with dioxane/NaHCO3 to give 
intermediate 3 as H-Lys-OCD12. The reaction was repeated as the above steps to give the 
crude product with intermediates 2 and 3. The resulting sticky paste was recrystallised from 
the mixed solvent of acetonitrile and petroleum ether to give white crystal as CDL12.
Chemical analysis of lipids
1H and 13C NMR spectra were measured at 400 and 100 MHz, respectively, on a Varian 
Mercury Plus 400 spectrometer. High resolution electrospray ionization mass spectrometry 
was performed using a Q-Tof Micro (Micromass Inc., Manchester, UK). IR spectra were 
recorded using an IRPrestige-21 (Shimadzu, JAPAN). HPLC was performed on a LC-20AB 
(Shimadzu, JAPAN) with a C18 column, 1% TFA in methanol/water mobile phase (85:15), 
the flow rate of 0.8 mL/min.
Preparation and characterisation of liposomes
The protocol for preparation of liposomes based on CDL12, CDL14, CDO12 and CDO14 
lipids was optimised to obtain high-quality delivery systems. The lipids were formulated in 
combination with the neutral lipid DOPE in 1:1 molar ratio. To prepare liposomes, a suitable 
amount of lipid and DOPE were dissolved in 1 mL of chloroform in a 5 mL glass vial. The 
solvent was removed under a stream of nitrogen gas, followed by high-vacuum desiccation. 
The dry lipid film was resuspended in 1 mL distilled water to give liposomes in a 
concentration of approximately 1 mg/mL. The liposome/DNA complexes of varying weight 
ratios (N/P) were prepared by mixing liposomes with plasmid solutions 20 min before use.
Particle size and Zeta potential measurements
The particle size and Zeta potential were measured with a Malvern ZetaSizer Nano series 
(Westborough, MA) at room temperature. All the lipoplexes of varying N/P ratios ranging 
from 1 to 8 were prepared with pGL3 plasmid. For the measurement of particle size and 
Zeta potential, 20 µL of the liposomes or lipoplexes were diluted to 1 mL with distilled 
water.
Agarose gel retardation assay
The lipoplexes of varying N/P ratios ranging from 0 to 8 were prepared with pGL3 plasmid. 
The lipoplexes were electrophoresed in 1.2 % agarose gel containing GelRed and Tris-
acetate (TAE) running buffer at 90 V for 40 min. DNA bands were visualised in a gel 
documentation unit (Syngene, Britain).
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In vitro pDNA transfection
Hep-2 and NCI-H460 cells were seeded in 24-well plates (5.0 × 104 cells/well), and 
incubated at 37 °C under 5 % CO2 until approximately 80 % confluence was attained. The 
medium was removed and replaced with 100 µL serum-free DMEM per well. Cationic 
liposome/DNA lipoplexes were then added to the plates and incubated for 4 h at 37 °C. The 
medium was then replaced with DMEM containing 10 % FBS and 1 % antibiotics, and the 
cultures were maintained at 37 °C under 5 % CO2 for 48 h.
The expression of green fluorescent protein was measured using an inverted fluorescence 
microscope (Olympus IX71, Japan). Relative luciferase activity was assessed using a Bright-
Glo™ Luciferase Assay System and Synergy™ 2 Multi-Detection Microplate Reader. 
Briefly, the growth medium was removed from each well, and luciferase activity was 
measured after lysis buffer was added. The total protein concentration in the cell lysate was 
measured using a BCA protein assay kit and luciferase activity was expressed as relative 
light units (RLU) per mg protein.
In vitro siRNA transfection
A549 cells expressing firefly luciferase were seeded in 12-well plates (1.0 × 105 per well) 
approximately 24 h before experiments. Cells were treated with different lipid formulations 
at the anti-luciferase siRNA concentration of 40 nM in Opti-MEM at 37 °C for 4 h. Cells 
were washed with DPBS, followed by incubation with lysis buffer at room temperature for 
20 min.
Fluorescence intensity in cell lysate was determined using a Perkin-Elmer LS 50B 
luminescence spectrometer (Norwalk, CT) (λex, 494 nm; λem, 519 nm). Cell lysate (5 µg per 
well) was dissolved in BCA protein assay reagent, and total protein concentrations 
determined at 570 nm. The silencing rate is expressed as relative light units (RLU) per 
microgram of total protein.
Cytotoxicity of the cationic liposomes
The assay was performed in 96-well plates by maintaining the N/P weight ratios as used in 
the transfection experiments. The cells were seeded in 96-well plates and incubated at 37 °C 
under 5 % CO2 for 24 h to get a confluence of about 80 %. After the replacement of 
medium, the liposomes/DNA complexes were added to the cells for further culture at 37 °C 
under 5 % CO2 for 24 h, and then MTT (20 µL, 5 mg/mL) was added and kept for 4.5 h. The 
absorbance at 570 nm was monitored by using the enzyme mark instrument (Sunrise Tecan, 
Australia).
Animals
In vivo studies were carried out on BALB/c nude mice of age 4–6 weeks. All experiments 
performed on the animals were in accordance with and approved by the Institutional Animal 
Care and Use Committee at University of North Carolina.
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In vivo gene silencing study
Combined siRNAs against c-Myc and VEGF (1:1) were co-delivered by CDO14 liposome. 
The tumor-bearing mice were injected IV times every 3 days via tail vein with lipoplexes at 
the N/P ratio of 3:1 (with a dose of 0.45 mg total siRNA/kg). One day after the third 
injection, the mice were killed and the tumor-loaded lungs were collected for the preparation 
of paraffin embedded sections (4-5 µm thick). Expressions of c-Myc and VEGF in the 
sections were examined immunohistochemically using the antibodies from a kit in 
accordance with the product protocol.
TUNEL assay
TUNEL staining was performed as recommended by the manufacturer’s protocol (Promega, 
Madison, WI). Tumor-bearing mice were given i.v. injections of the siRNA formulated in 
the CDO14 on days 9 and 10. Twenty-four hours after the second injection, the mice were 
killed, and the tumor-loaded lungs were collected for the TUNEL staining. The nuclei were 
counterstained with hematoxylin, and the samples were imaged using an inverted 
fluorescence microscope (Olympus IX71, Japan).
Toxicity of the cationic liposomes in vivo
The tumor-bearing mice were i.v. injected with siRNA formulated in the targeted liposome 
at 3:1 doses, and the serum cytokine level was determined with Olympus AU400 Automatic 
Biochemistry Analyzer. Mouse body weight was also monitored.
Statistical analysis
The data were presented as mean values ± SD. The statistical significance was determined 
using two-way analysis of variance. P values <0.05 were considered significant.
3 Results and discussion
Design and synthesis of cationic lipids
The tri-peptide cationic lipids designed are composed of three biocompatible molecular 
moieties: tri-lysine peptides or tri-ornithine peptides (the cationic headgroup), carbamate 
(the linker), and two hydrocarbon chains (hydrophobic tails). These tri-peptide cationic 
lipids were prepared by adapting a straight forward procedure (Scheme 1). Intermediate 1 
was obtained from carbonyldiimidazole, dodecyl alcohol and triethylenetetra-amine. The 
synthesis of intermediate 2 started with Fmoc and Boc groups protected lysine. After the 
condensation under HATU activation and the deprotection by using TFA and NaHCO3, 
intermediate 3 could be given. Following the same procedure by using another 2 mol Boc 
and Fmoc protected lysine; we got tri-peptide cationic lipids for further chemical analysis 
and biological study.
The structures and purities of tri-peptide cationic lipids were characterised by electrospray 
ionisation-mass spectrometry (ESI-MS), proton nuclear magnetic resonance spectroscopy 
(1H NMR, 13C NMR), infrared (IR) spectroscopy, and high pressure liquid chromatography 
(HPLC) (Fig. S1–S4, ESI†). The analytical data of these compounds are listed under the 
figures in the ESI† to show that tri-peptide cationic lipids were successfully obtained.
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Particle size, and Zeta-potential of tri-peptide cationic liposomes and lipoplexes
Our previous study showed that liposomes had higher transfection efficiency with equivalent 
molar ratio of DOPE, so the liposomes were prepared by using the tri-peptides with DOPE 
as co-lipid at a molar ratio of 1:1. The dynamic light scattering showed the particle sizes of 
these liposomes were from 70 nm to 150 nm, those for the lipoplexes of CDO14/DNA were 
from 200 nm to 400 nm in the N/P ratio range from 1:1 to 8:1 (Fig. 2, 3). Zeta potentials of 
liposomes were between 40–60 mV, which ensured the stability of the liposomes for at least 
three months. Zeta potentials of the lipoplexes of CDO14/DNA were found to increase from 
−50 mV to nearly 0 mV with the increase of the N/P ratios from 1:1 to 8:1 (Fig. 2, 3). The 
sizes and Zeta potentials were in the ranges suitable for gene transfection.27 The 
morphological characteristics were directly visualised by transmission electron microscopy 
(TEM) (Fig. S5, ESI†). Images obtained from CDO14 liposome and CDO14 liposome/DNA 
lipoplex at the N/P ratio of 3:1 revealed well-defined spherical structures.
DNA-binding assay
DNA-binding with liposomes is a key factor for gene transfection.28 Therefore, the 
electrostatic binding interactions between plasmid DNA and the tri-peptide cationic 
liposomes were measured by the gel retardation assay across the N/P ratios of 0:1–8:1. 
Findings in the gel retardation assay revealed all the liposomes could start to retard the 
plasmid DNA at the N/P ratio of 0.5:1. They could nearly completely retard pDNA at higher 
N/P ratios of 6:1, 6:1, 6:1 and 3:1 for CDL12, CDL14, CDO12 and CDO14, respectively. 
Though all the above liposomes could bind pDNA at higher N/P ratios, the lower N/P ratio 
of CDO14 for retardation compared with other liposomes may reduce its dose required to 
obtain maximal transfection efficiency. The above results demonstrate that cationic 
liposomes can form DNA-liposomes complexes at different N/P ratios. This ensured the 
entry of pDNA into cells and the protection of pDNA from degradation by DNase. (Fig. S6, 
ESI†).
In vitro pDNA and siRNA transfection
The in vitro transfection of these liposomes was evaluated using pGFP-N2 plasmid DNA 
and pGL3 plasmid DNA against Hep-2 and NCI-H460 cells. The expression of pGFP-N2 
and pGL3 is illustrated in Fig. 4 (more details to see Fig. S7 and Fig. S8, ESI†) and Fig. 5, 
respectively. The results indicate that all the lipids were comparable to Lipofectamine 2000 
and DOTAP in terms of GFP and luciferase expression. They had higher transfection against 
Hep-2 cells than against NCI-H460 cells. The liposomes with ornithine headgroup also 
showed higher transfection than those with lysine headgroup, perhaps because they have 
smaller heads.
Through the above experiments, the transfection in cells will undergo the following process. 
First, the plasmid DNA binds to the tri-peptide head-groups of the cationic lipids. Then, the 
lipids/DNA lipoplexes will enter the Hep-2 cells and NCI-H460 cells (e.g., via endocytosis), 
and trypsin in the cell will hydrolyze the carbamate bond in the lipids. The hydrolization 
assists DNA to escape from the endosome for the subsequent transcription. The whole 
process is readily performed and thus enhances DNA transfection efficiency.
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Tri-peptide lipids were screened for the ability to deliver siRNA to A549 lung carcinoma 
cells which can stably express firefly luciferase (Fig. 6). The efficacy of siRNA delivery by 
these tri-peptide lipids was determined by treating cells with siRNA-complexes, prepared 
using a firefly luciferase targeting siRNA(siLuc).29–30 Overall, all four lipids showed gene 
silence compared with the control. Three of them were better than DOTAP, and CDO14 and 
CDL14 were slightly better than Lipofectamine 2000, silencing nearly 75 % of luciferase in 
A549 cells. Much work has been carried out on modifying cationic lipids for use in gene 
transfection, to determine if there is a ‘best’ chain length.31 However, solid conclusions are 
rarely obtained, for the conclusions of these studies are frequently contradictory. In this 
study, CDL14 and CDO14 showed superior siRNA delivery. It may maintain an appropriate 
balance between fluidity and rigidity for entering into cells, and have the ability to release 
siRNA in cells due to the carbamate linker.
Cytotoxicity of the cationic liposomes
Cytotoxicity of gene delivery materials could be measured by the MTT method. Cell 
viabilities after exposure to lipids, CDL12, CDL14, CDO12 and CDO14, were evaluated in 
NCI-H460 cells and Hep-2 cells across the entire range of N/P weight ratios used in the 
transfection experiments. Cells could tolerate all the lipids at relatively low N/P ratios 
(under 4:1), better than the commercial liposomes, Lipofectamine 2000 and DOTAP (Fig. 
7). The lower cytotoxicity of these lipids should be contributed to the nature of the peptide 
headgroups, as they are more biocompatible over quaternary ammonium with cells, thus 
increasing the toleration of cells to them.19, 24
In vivo gene silencing study
Since cationic lipid CDO14 showed optimal in vitro pDNA and siRNA transfection, its in 
vivo delivery was studied. Combined siRNAs against c-Myc and VEGF (1:1) were delivered 
by CDO14 liposome. The A549 lung tumor bearing mice were injected 3 times every 3 days 
via tail vein with lipoplexes at the N/P ratio of 3:1 (with a dose of 0.45 mg total siRNA/kg). 
As immunohistochemistry could give clear conclusion of RNA interference,17, 31–32 the 
gene silencing activity was measured by using this method. As shown in Fig. 8, the protein 
expression of c-Myc and VEGF in the lung tumor was suppressed by the combined siRNAs 
delivered with CDO14 liposome. The results indicate that the combined siRNAs formulated 
in CDO14 liposome were able to simultaneously silence the expressions of the target 
oncogenes in the lung tumors. The successful interference of combined siRNAs to different 
genes opens a door by silencing multi-oncogenic pathways by using tri-peptide cationic 
lipids. This increases the possibility of CDO14 as a potential candidate for the further in vivo 
study and clinical trials.
TUNEL assay
Apoptotic induction plays an essential role in the suppression of tumor cell proliferation.33 
We examined the apoptosis induced by siRNAs using the TdT dUTP nick end-labeling 
(TUNEL) staining (Fig. 9). As shown in the figure, the number of TUNEL-positive cells 
increased after intravenous injections of siRNA formulated in CDO14 liposome. Intravenous 
injections of siRNA in the control group showed only a slight increase in TUNEL-positive 
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cells. No significant apoptotic induction was observed in other treatment groups. These 
results suggest that this formulation triggered cell death and might play a critical role in 
regulating the survival of A549 lung cancer cells in vivo.
Toxicity of the cationic liposomes in vivo
In addition to therapeutic effect, toxicity is a crucial parameter of a therapeutic agent for 
clinical use. At the therapeutic dose (0.45 mg/kg), the formulation did not induce significant 
elevation of renal indicators and liver enzymes, including blood urea nitrogen (BUN), 
creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Table 1). 
Additionally, the body weights of mice were stably increased after post injection of 
lipoplexes at the therapeutic dose (Fig. 10). The results indicate the formulation containing 
CDO14 did not induce obvious toxicity to mice. The toxicity to cells and animals is a major 
obstacle for the clinical trials of cationic lipids, as the cationic lipids with quaternary 
ammonium headgroup can become cytotoxic by interacting with critical enzymes such as 
PKC.34 Therefore, the toxicity of cationic lipids is mainly determined by their cationic 
nature. The replacement of quaternary ammonium with tri-peptide increased the affinity and 
biocompatibility, thereby, increasing their transfection and lowering toxicity.
4 Conclusion
In summary, we selected the tri-peptide Lys-Lys-Lys and Orn-Orn-Orn as the headgroups 
for the gene delivery study, because both lysine and ornithine are found in a number of 
structurally characterized DNA binding domains of proteins. These cationic lipids are 
relatively simple to synthesize by using standard peptide chemistry, and their chemical 
structures can readily be tailored for effective interaction with DNA. The in vitro delivery 
results of pDNA and siRNA by these tri-peptide lipids against NCI-H460 and Hep-2 tumor 
cells show that they could lead to superior transfection compared to conventional non-viral 
transfection reagents. They also showed lower cytotoxicity against the two tumor cells. The 
lipid CDO14 with ornithine as headgroup and 14 carbon atom alkyl groups at tails 
demonstrated better transfection over other lipids. It was selected to be used for in vivo 
evaluation. It showed not only enhanced transfection activity, but also very low toxicity in 
vivo. CDO14 could be able to deliver combined siRNAs against c-Myc and VEGF for 
silencing distinct oncogenic pathways in lung tumors of mice. The results of this study 
strengthen the validity of the peptides based cationic lipids as a drug delivery vehicle for 
cancer therapy.
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Structures of tri-peptide cationic lipids CDL12, CDL14, CDO12 and CDO14.
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Particle size and Zeta potential of tri-peptide liposomes. Liposomes (20 µL) were diluted in 
1 mL distilled water. Particle size (A) and Zeta potential (B) were measured using a Malvern 
ZetaSizer. The PDI of CDL12, CDL14, CDO12, CDO14, Lipofectamine 2000 and DOTAP 
was 0.286, 0.262, 0.296, 0.422, 0.306 and 0.242, respectively.
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Particle size and Zeta potential of tri-peptide lipoplexes. Particle size (A) and Zeta potential 
(B) were measured using a Malvern ZetaSizer. The PDI of lipoplexes from left to right was 
0.427, 0.292, 0.391, 0.192, 0.296, 0.210, 0.206 and 0.189, respectively.
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Fluorescent images (20×10) of GFP gene expression in NCI-H460 and Hep-2 cells using tri-
peptide liposomes at the N/P ratio of 3:1 (the amount of pGFP-N2 was 0.5 µg/well, 96-well 
plates). As controls, Lipofectamine 2000 and DOTAP were used at the N/P ratio of 3:1. (A: 
NCI-H460, B: Hep-2; 1–6 were CDL12, CDL14, CDO12, CDO14, Lipofectamine 2000 and 
DOTAP, respectively.)
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Luciferase expression in tumor cells using tri-peptide liposomes at N/P ratios from 1:1 to 8:1 
(the amount of pGL3 was 0.5 µg/well, 96-well plates). As controls, DOTAP and 
Lipofectamine 2000 were used at an N/P ratio of 3:1, as suggested by the protocols. (A) 
NCI-H460, (B) Hep-2. Statistical analysis was accomplished by a two-way ANOVA: *, P < 
0.05; **, P < 0.01.
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Gene silence in A549 cells was determined by luciferase assay after 48 h. A549 cells were 
treated with firefly luciferase targeting siRNA-peptide lipid complexes at the N/P ratio of 
3:1 (the amount of pGL3 was 0.5 µg/well, 96-well plates). Statistical analysis was 
accomplished by a two-way ANOVA: *, P < 0.05; **, P < 0.01.
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Cytotoxicity of the tri-peptide lipids against NCI-H460 and Hep-2 cells, 48 h after the 
addition of lipoplexes formulated from liposomes and GFP plasmids. The cell viability of 
negative control cells was designated as 100 %. The positive controls were Lipofectamine 
2000 and DOTAP, which were formulated with GFP plasmids to form lipoplexes at a ratio 
of 3:1 (A: NCI-H460, B: Hep-2).
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Immunohistochemical analysis of the lung tumor. SiRNAs against c-Myc and VEGF were 
delivered with (left) or without (right) CDO14 liposome.
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TUNEL staining of A549 lung tumors on day 9 after 3 consecutive i.v. injections on day 0, 
3, 6 of combined siRNAs.
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The weight changes of mice after injections of lipoplex.
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Synthesis of tri-peptide lipid CDL12. Reaction conditions: (A) CH2Cl2, 40 °C, 3 h; (B) 
THF, 40 °C, 3 h; (C) H2O, 27 °C, 30 h; (D) room temperature, 4 h; (E), (H), (I) CH2Cl2, 20 
°C, 12 h; (F), (J) CHCl3, 4 °C, 2 h; (G), (K) Dioxane, room temperature, 2 h.
Reagents: (Boc)2O = Di-tert-butyl dicarbonate, Fmoc-OSu = 9-Fluorenylme-thyl-
succinimidyl-carbonate, HATU = Azabenzotriazol-1-yl)-N,N,N',N'-tetr-amethyluronium 
hexafluorophosphate, TFA = Trifluoroacetic acid.
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Table 1




AST U/L ALT U/L
CDO14 Lipoplex
18 0.1 87 51
20 0.2 102 59
24 0.2 82 59
Control
20 0.1 112 97
19 0.1 157 71
Normal 8–33 0.1–0.2 54–298 17–77
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